Return to search

Regenacy Pharmaceuticals lands $30m Series A

Waltham, Massachusetts-based Regenacy Pharmaceuticals, a developer of treatments for diabetic and other peripheral neuropathies, has secured $30 million in Series A financing.

Waltham, Massachusetts-based Regenacy Pharmaceuticals, a developer of treatments for diabetic and other peripheral neuropathies, has secured $30 million in Series A financing. Cobro Ventures and Taiwania Capital Management Corporation led the round with participation from other investors that included 3E Bioventures Capital, Yonjin Capital, VIVA Biotech Holdings and TA YA VENTURE HOLDINGS LIMITED.

Source: Press Release